Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Urinary tract infections (UTIs) are common drivers of antibiotic use. The minimal effective duration of antibiotic therapy for UTIs is unknown, but any reduction is important to diminish selection pressure for antibiotic resistance, costs, and drug-related side-effects. The aim of this study was to investigate whether an algorithm based on procalcitonin (PCT) and quantitative pyuria reduces antibiotic exposure.
Methods: From April 2012 to March 2014, we conducted a factorial design randomized controlled open-label trial. Immunocompetent adults with community-acquired non-catheter-related UTI were enrolled in the emergency department of a tertiary-care 600-bed hospital in northwestern Switzerland. Clinical presentation was used to guide initiation and duration of antibiotic therapy according to current guidelines (control group) or with a PCT-pyuria-based algorithm (PCT-pyuria group). The primary endpoint was overall antibiotic exposure within 90 days. Secondary endpoints included duration of the initial antibiotic therapy, persistent infection 7 days after end of therapy and 30 days after enrollment, recurrence and rehospitalizations within 90 days.
Results: Overall, 394 patients were screened, 228 met predefined exclusion criteria, 30 declined to participate, and 11 were not eligible. Of these, 125 (76% women) were enrolled in the intention-to-treat (ITT) analysis and 96 patients with microbiologically confirmed UTI constituted the per protocol group; 84 of 125 (67%) patients had a febrile UTI, 28 (22%) had bacteremia, 5 (4%) died, and 3 (2%) were lost to follow-up. Overall antibiotic exposure within 90 days was shorter in the PCT-pyuria group than in the control group (median 7.0 [IQR, 5.0-14.0] vs. 10.0 [IQR, 7.0-16.0] days, P = 0.011) in the ITT analysis. Mortality, rates of persistent infections, recurrences, and rehospitalizations were not different.
Conclusions: A PCT-pyuria-based algorithm reduced antibiotic exposure by 30% when compared to current guidelines without apparent negative effects on clinical outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427918 | PMC |
| http://dx.doi.org/10.1186/s12916-015-0347-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epidemiology of erysipelas and necrotising soft tissue infections.
Dan Med J
August 2025
Department of Regional Health Research, University of Southern Denmark.
Introduction: Erysipelas is a common disease in the emergency department, whereas necrotising soft tissue infections (NSTIs) are rare but more severe. The study aimed to investigate the prevalence, incidence, population-based incidence rate, one-year mortality and clinical presentation of erysipelas and NSTIs, and the aetiology, treatment and recurrence of erysipelas.
Methods: This was a population-based cohort study including acute non-trauma patients ≥ 18 years old with erysipelas or NSTIs from the Region of Southern Denmark in the period from 1 January 2016 to 19 March 2018.
A Silent Invader: Asymptomatic Rhodococcus Infection Unmasked in A Patient with Ectopic ACTH-Dependent Cushing's Syndrome.
Eur J Case Rep Intern Med
August 2025
Charleston Area Medical Center, Charleston, USA.
Introduction: species, particularly , are rare opportunistic pathogens that typically affect immunocompromised individuals. These infections usually present with respiratory or systemic symptoms and are often linked to environmental exposure. Asymptomatic infections are exceedingly rare and pose unique diagnostic and therapeutic challenges.
View Article and Find Full Text PDFJanus Kinase Inhibitors as A Breakthrough Treatment for Refractory Dissecting Cellulitis of the Scalp.
Eur J Case Rep Intern Med
August 2025
Dermatology Department, Ain Shams University Hospital, Cairo, Egypt.
Background: Dissecting cellulitis of the scalp (DCS) is a rare, chronic neutrophilic dermatosis that is often refractory to conventional therapies.
Case Report: We present a 29-year-old male with treatment-resistant DCS who achieved rapid and sustained remission following off-label use of tofacitinib, a Janus kinase (JAK) inhibitor. Previous therapies, including antibiotics, corticosteroids, and isotretinoin, had failed.
Enhancing Antifungal Efficacy and Stability of Nystatin Liposomes Through Chitosan and Alginate Layer-by-Layer Coating: In vitro Studies Against .
Int J Nanomedicine
September 2025
Department of Pharmaceutics and Pharmaceutical Technology, Universitas Padjadjaran, Sumedang, West Java, 45363, Indonesia.
Background: Candidiasis, predominantly caused by , poses a significant global health challenge, especially in tropical regions. Nystatin is a potent antifungal agent that is hindered by its low solubility and permeability, limiting its clinical efficacy.
Methods: This study aimed to investigate the potential of a layer-by-layer (LBL) coating system, employing chitosan and alginate, to improve the stability, entrapment efficiency (%EE), and antifungal efficacy of nystatin-loaded liposomes against Candida albicans.
Black hairy tongue (BHT), or lingua villosa nigra, is a rare adverse effect of linezolid, an antibiotic frequently used in the treatment of multidrug-resistant tuberculosis (MDR-TB). We present a case of a 24-year-old female who developed BHT while receiving linezolid as part of a longer regimen for MDR-TB. The patient exhibited a typical BHT presentation, with painless brown-to-black discoloration on the posterior dorsal surface of her tongue, appearing 25 days after initiating linezolid therapy.
View Article and Find Full Text PDF